AI Insight
This study identifies poly(ADP-ribose) (PAR), a product of the enzyme PARP1, as an elevated biomarker in the cerebrospinal fluid of patients with mild cognitive impairment and Alzheimer's disease, with levels correlating with established markers of amyloid pathology. Using a familial Alzheimer's disease mouse model, the researchers demonstrate that genetic deletion of PARP1 reduces amyloid accumulation, limits neurodegeneration, and preserves cognitive function. These findings suggest that PARP1-mediated signaling plays a contributory role in the progression of Alzheimer's disease pathology.
Why it matters
PARP1 inhibitors already exist as approved cancer therapeutics, meaning this research could accelerate the evaluation of existing compounds as candidate treatments for Alzheimer's disease. Additionally, PAR may offer a clinically accessible cerebrospinal fluid biomarker to track disease progression or therapeutic response.
Proceedings of the National Academy of Sciences, Volume 123, Issue 20, May 2026. <br/>SignificanceOur study identifies poly(ADP-ribose) (PAR) as an elevated biomarker in the cerebrospinal fluid of patients with mild cognitive impairment and Alzheimer’s disease, correlating with established markers of amyloid pathology. We demonstrate that …